Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response: 0.5										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HAASER CHARLES B						2. Issuer Name and Ticker or Trading Symbol YIELD10 BIOSCIENCE, INC. [YTEN]									ationship of Reporting k all applicable) Director Officer (give title		ng Pe	rson(s) to Is 10% O Other (vner	
(Last) (First) (Middle) C/O YIELD10 BIOSCIENCE, INC. 19 PRESIDENTIAL WAY						3. Date of Earliest Transaction (Month/Day/Year) 02/11/2021									VP Fin & Chief Accting Office					
(Street) WOBUR (City)			1801 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indi Line) X						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date				2. Transac Date (Month/Da		Exec if any	Deemed ecution Date, ny onth/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			, 4 and Sec Ben Owr		Amount of curities neficially ned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
				Code	v	Amount			(A) c (D)	Pri	Trans		action(s) 3 and 4)			(Instr. 4)				
Common Stock 02/11/					:021				F		693(1)	D	\$2	22.77	77 2,775		D			
Common Stock															3,	306 ⁽²⁾		I	By 401(k) Plan	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) Exc	if any	emed ion Date, /Day/Year)	4. Transaction Code (Instr. 8)				6. Date Expirati (Month/	ion Da		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly OF	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares	er						

Explanation of Responses:

- 1. Represents shares withheld in payment of withholding taxes upon vesting of RSUs granted 2/11/20.
- 2. Shares acquired as Company matching contributions under the Yield10 Bioscience, Inc. 401(k) Plan.

/s/ Megan N. Gates, attorney-

02/16/2021

in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.